DJIA 18,285.74 0.34 0.00%
NASDAQ 5,090.79 19.05 0.38%
S&P 500 2,130.82 4.97 0.23%
market minute promo


company name or ticker

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q3 2014 Results - Earnings Call Transcript

Super Important Biotech and Drug Stock Events for November

AstraZeneca's Lynparza a Step Closer to European Approval - Analyst Blog

3 Beaten Down Biotech Stocks to Buy Now

The share prices of Dynavax Technologies, CellDex Therapeutics, and Clovis Oncology have all plunged this year. Here is why I think these beaten down biotechs are now compelling buys.

Clovis Oncology (CLVS) Soars: Stock Adds 13.2% is Session - Tale of the Tape

Big News for These 5 Stocks From ESMO

But smaller biotechs Clovis Oncology and Exelixis also benefit from the big boys' data.

3 Unusual-Volume Stocks Triggering Breakout Trades

Clovis Shares Higher on Improved Outlook for Lung Cancer Drug

Clovis Oncology (CLVS) CEO Pat Mahaffy Presents at Morgan Stanley Healthcare Conference (Transcript)

Clovis Oncology (CLVS) Falls: Stock Goes Down 6.8% - Tale of the Tape

See More Articles...